Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
24.52 USD | +2.25% | +20.20% | +210.77% |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | 6.29M | Capitalization | 370M |
---|---|---|---|---|---|
Net income 2024 * | -71M | Net income 2025 * | -74M | EV / Sales 2024 * | - |
Net cash position 2024 * | 217M | Net cash position 2025 * | - | EV / Sales 2025 * | 58.8 x |
P/E ratio 2024 * |
-4.93
x | P/E ratio 2025 * |
-6.19
x | Employees | 45 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 93.39% |
Latest transcript on Jasper Therapeutics, Inc.
1 day | +2.25% | ||
1 week | +20.20% | ||
Current month | +2.72% | ||
1 month | -9.52% | ||
3 months | +103.82% | ||
6 months | +245.25% | ||
Current year | +210.77% |
Managers | Title | Age | Since |
---|---|---|---|
Ronald Martell
CEO | Chief Executive Officer | 62 | 22-03-14 |
Herbert Cross
DFI | Director of Finance/CFO | 52 | 23-09-21 |
Luca Di Noto
CTO | Chief Tech/Sci/R&D Officer | - | 19-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Ronald Martell
CEO | Chief Executive Officer | 62 | 22-03-14 |
Thomas Wiggans
CHM | Chairman | 72 | Oct. 31 |
Kurt von Emster
BRD | Director/Board Member | 56 | 21-09-23 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-03 | 24.52 | +2.25% | 58,055 |
24-05-02 | 23.98 | -0.04% | 59,567 |
24-05-01 | 23.99 | +0.50% | 79,875 |
24-04-30 | 23.87 | +8.90% | 90,969 |
24-04-29 | 21.92 | +7.45% | 35,469 |
Delayed Quote Nasdaq, May 03, 2024 at 04:30 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+210.77% | 370M | |
+21.85% | 546B | |
-4.77% | 359B | |
+16.97% | 323B | |
+5.69% | 290B | |
+13.68% | 234B | |
+3.65% | 198B | |
-11.12% | 194B | |
+8.08% | 167B | |
-3.40% | 157B |
- Stock Market
- Equities
- JSPR Stock